Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Phathom Pharmaceuticals Inc’s stock clocked out at $9.18, down -5.26% from its previous closing price of $9.69. In other words, the price has decreased by -$5.26 from its previous closing price. On the day, 0.77 million shares were traded. PHAT stock price reached its highest trading level at $9.7 during the session, while it also had its lowest trading level at $9.18.
Ratios:
To gain a deeper understanding of PHAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.54 and its Current Ratio is at 3.58.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 14, 2025, initiated with a Overweight rating and assigned the stock a target price of $23.
On May 03, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on January 05, 2024, while the target price for the stock was revised from $23 to $26.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 21 ’25 when Topper James N bought 3,780 shares for $3.86 per share. The transaction valued at 14,609 led to the insider holds 59,403 shares of the business.
Topper James N bought 6,300 shares of PHAT for $20,919 on May 14 ’25. The Director now owns 55,623 shares after completing the transaction at $3.32 per share. On May 13 ’25, another insider, Topper James N, who serves as the Director of the company, bought 1,120 shares for $3.16 each. As a result, the insider paid 3,543 and bolstered with 49,323 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PHAT now has a Market Capitalization of 640893440 and an Enterprise Value of 1021838208. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.83. Its current Enterprise Value per Revenue stands at 12.483 whereas that against EBITDA is -3.578.
Stock Price History:
The Beta on a monthly basis for PHAT is 0.46, which has changed by -0.2754538 over the last 52 weeks, in comparison to a change of 0.1116153 over the same period for the S&P500. Over the past 52 weeks, PHAT has reached a high of $19.71, while it has fallen to a 52-week low of $2.21. The 50-Day Moving Average of the stock is 40.65%, while the 200-Day Moving Average is calculated to be 9.38%.
Shares Statistics:
It appears that PHAT traded 2.78M shares on average per day over the past three months and 1082320 shares per day over the past ten days. A total of 69.64M shares are outstanding, with a floating share count of 37.85M. Insiders hold about 45.79% of the company’s shares, while institutions hold 47.35% stake in the company. Shares short for PHAT as of 1749772800 were 11038334 with a Short Ratio of 3.07, compared to 1747267200 on 11177554. Therefore, it implies a Short% of Shares Outstanding of 11038334 and a Short% of Float of 26.38.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
